Abstract
Introduction and Objectives The availability of a limited arsenal of antibacterial agents effective against Burkholderia pseudomallei, the causative agent of melioidosis, together with sporadic reports of emergence of
resistance necessitates an evaluation of in vitro activity of new antimicrobials against
clinical B. pseudomallei isolates. Cefiderocol (CFDC), a novel siderophore cephalosporin, and ceftazidime-avibactam
(CZA), a new β lactam combination agent, have shown promising results for the treatment
of difficult-to-treat Gram-negative bacilli infections with limited treatment options.
This study was conducted to determine the in vitro activity of CFDC and CZA against
a contemporary collection of 60 B. pseudomallei clinical isolates.
Materials and Methods Minimum inhibitory concentrations (MIC) of CFDC and CZA were determined by broth
microdilution and E-test, respectively. The performance of disk diffusion was also
evaluated for CFDC.
Results All B. pseudomallei isolates were susceptible to CFDC and CZA with MIC range of 0.125 to 2 mg/L and 0.19
to 1 mg/L, respectively. Zone diameters for CFDC ranged from 31 to 40 mm.
Conclusion CFDC and CZA exhibited excellent in vitro activity against 60 B. pseudomallei isolates. Further pharmacokinetic-pharmacodynamics studies and clinical trials are
needed to prove the clinical efficacy of CFDC and CZA in the treatment of melioidosis.
Keywords
Burkholderia pseudomallei
- Cefiderocol - Ceftazidime-avibactam
